Wheat Ridge, CO – According to filings with the U.S. Securities and Exchange Commission, Ablacon is raising $29,999,998.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Martin Grasse played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ablacon

Atrial Fibrillation (AF) is the most frequent arrhythmic disorder of the heart. At Ablacon, we leverage our expertise in electrophysiology, computer vision and deep learning to build a real-time high-precision AI-based diagnosis system. We are an international team based in Lausanne (CH), Denver, CO (US) and Munich (DE) with a partner clinic in Hamburg (DE).

To learn more about Ablacon, visit http://ablacon.com/

Contact:
Martin Grasse, Chief Operating Officer
303-955-5620
https://www.linkedin.com/in/martygrasse/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved